Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Samoylenko, Igor
NCT05578820: Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid	Completed	1	21	RoW	Stimotimagene copolymerplasmid, AntioncoRAN-M, Ganciclovir, Cymeven®	Gene Surgery LLC	Sarcoma, Melanoma, Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms, Penile Neoplasms, Anus Neoplasms	04/24	04/24
RATIONALE, NCT05171374: pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE	Recruiting	N/A	500	RoW	Dabrafenib, Trametinib	MelanomaPRO, Russia, Novartis	Melanoma Stage III, Melanoma Stage IV, Melanoma	09/23	09/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Samoylenko, Igor
NCT05578820: Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid	Completed	1	21	RoW	Stimotimagene copolymerplasmid, AntioncoRAN-M, Ganciclovir, Cymeven®	Gene Surgery LLC	Sarcoma, Melanoma, Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms, Penile Neoplasms, Anus Neoplasms	04/24	04/24
RATIONALE, NCT05171374: pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE	Recruiting	N/A	500	RoW	Dabrafenib, Trametinib	MelanomaPRO, Russia, Novartis	Melanoma Stage III, Melanoma Stage IV, Melanoma	09/23	09/24